Assembly Biosciences Inc. has disclosed heteroaryl carboxamide derivatives reported to be useful...

Cgenetech (Suzhou, China) Co. Ltd. has described glucagon-like peptide 1 (GLP-1) receptor agonists reported to be useful for the treatment of diabetes.

Researchers at Mossakowski Medical Research Centre at the Polish Academy of Sciences (PAS) and The University of Warsaw have divulged peptides reported to be useful for the treatment of pain.

Impact Therapeutics (Shanghai) Inc. has identified substituted triazoloheteroaryl compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Monte Rosa Therapeutics Inc. has synthesized molecular glue degraders acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and cereblon (CRBN) interaction inducers for GSPT1 degradation reported to be useful for the treatment of cancer.

Shanghai Meiyue Biotech Development Co. Ltd. has disclosed serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of metabolic, autoimmune diseases, cardiovascular, dermatological, endocrine disorders, transplant rejection, fibrosis and inflammatory disorders.

Haisco Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon binding moiety covalently coupled to poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) targeting moiety through a linker acting as PARP-1 degradation inducers reported to be useful for the treatment of cancer.

Kinnate Biopharma Inc. has identified Raf kinase inhibitors reported to be useful for the treatment of cancer.

Dana-Farber Cancer Institute Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) binding moiety covalently linked to a histone-lysine N-methyltransferase, H3 lysine-79 specific (DOT1L) targeting moiety via linker reported to be useful for the treatment of cancer.

Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized compounds targeting protein cereblon (CRBN) and their PROTACs (proteolysis targeting chimeras) reported to be useful for the treatment of cancer, anemia, transplant rejection, neurodegeneration, infections, autoimmune, inflammatory and metabolic disorders, among others.